Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sionna Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.sionnatx.com/
Year Founded: 2019
Status: Public
Industry Sector: N/A
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: N/A
Exchange/Ticker 1: NASDAQ:SION
Exchange/Ticker 2: N/A
Latest Market Cap: $660,751,296
BioCentury | Feb 19, 2025
Finance
China competition. Plus: FDA firings and biotech IPOs
Why U.S. biotechs should embrace the challenge from China biotech
BioCentury | Feb 7, 2025
Finance
Strong demand for Sionna latest good sign for IPOs: Public Equity Report
Vertex competitor posts a first-day gain after an upsized offering; plus financings for Gh Research and Tectonic
BioCentury | Feb 1, 2025
Finance
Metsera, Maze land on NASDAQ as IPO queue grows
BioCentury’s Public Equity Report: MASH data drive follow-ons for Akero, 89bio
BioCentury | Jan 25, 2025
Finance
Private biotechs halfway through valuation reset
51% of biotechs still haven’t raised new capital or advanced lead clinical asset since financing in 2020-22 period
BioCentury | Jan 24, 2025
Finance
Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs
In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash
BioCentury | Jan 22, 2025
Finance
Biotech bulls and bears in 2025
Public Markets Preview: Will political uncertainty resolve in biotech’s favor or lead to economically damaging policy?
BioCentury | Jul 22, 2024
Deals
Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal
Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia
BioCentury | Jun 4, 2024
Management Tracks
New commercial heads for Illumina, UroGen, Invivyd
Plus: Jennifer Fitzpatrick hired as general counsel at Sionna
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
Items per page:
1 - 10 of 11